<DOC>
	<DOCNO>NCT01932541</DOCNO>
	<brief_summary>This study 8-week open-label trial test Lurasidone ( Latuda® ) treatment mania child adolescents Bipolar I , Bipolar II , Bipolar Spectrum disorder . We hypothesize Lurasidone safe , tolerable , effective improve core symptom bipolar disorder child adolescent age 6-17 .</brief_summary>
	<brief_title>Open-Label Study Latuda Treatment Mania Children Adolescents 6-17 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>1 . Male female subject 617 year age 2 . Subjects must weigh least 20 kg 3 . Subjects diagnosis bipolar I , bipolar II , bipolar spectrum disorder currently display manic , hypomanic , mixed symptom ( without psychotic feature ) , DSMIV ( Diagnostic Statistical Manual IV ) , manifest clinical evaluation and/or Mania module structure interview , complete study clinician . Bipolar Spectrum Disorder ( subthreshold bipolar disorder ) operationalized severe mood disturbance , meet DSMIV Criteria A bipolar disorder display few element Criteria B ( require 2 item elation category 3 irritability ) 4 . Subjects must score ≥ 20 YMRS ( Young Mania Rating Scale ) 5 . Subjects legal representative must level understanding sufficient communicate intelligently investigator study coordinator , cooperate test examination require protocol . 6 . Subjects legal representative must consider reliable reporter . 7 . Each subject his/her authorized legal representative must understand nature study . The subject 's authorized legal representative must sign informed consent document subject must sign informed assent document ( ≥ 7 year old ) . 8 . Subject must able participate mandatory blood draw . 9 . Subject must able swallow pill . 10 . Subjects comorbid PDD ( Pervasive Developmental Disorder ) depressive disorder allow participate study provide meet exclusionary criterion . 11 . For concomitant therapy use treat ADHD ( Attention Deficit Hyperactivity Disorder ) , subject must stable dose medication 1 month prior study enrollment , dose ADHD therapy change throughout duration study . 1 . Investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild . 2 . Serious , unstable illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 3 . Uncorrected hypothyroidism hyperthyroidism . 4 . Nonfebrile seizure without clear resolve etiology . 5 . DSMIV substance ( except nicotine caffeine ) dependence within past 6 month . 6 . Judged clinically serious suicidal risk CSSRS ( Columbia Suicide Severity Rating Scale ) score ≥ 4 . 7 . Any concomitant medication primary central nervous system activity specify Concomitant Medication portion Protocol . 8 . Current diagnosis schizophrenia . 9 . Mental retardation ( IQ &lt; 75 ) 10 . Pregnant nursing female 11 . Known hypersensitivity Latuda® 12 . A nonresponder history intolerance Latuda® , treatment adequate dos determine clinician . 13 . Severe allergy multiple adverse drug reaction . 14 . Subjects hematological disorder . 15 . Subjects diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Mania</keyword>
	<keyword>Bipolar I</keyword>
	<keyword>Bipolar II</keyword>
	<keyword>Bipolar Spectrum Disorder</keyword>
	<keyword>Pediatric</keyword>
</DOC>